Loading…
ABVC BioPharma, Inc. is projected to decline to $1.39 by 2027, a 0% move from its current price of $1.39. ABVC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.33 | $1.39 | $1.45 | -0.03% |
| May 30 | $1.31 | $1.39 | $1.47 | -0.06% |
| May 31 | $1.29 | $1.39 | $1.49 | -0.09% |
| Jun 1 | $1.28 | $1.39 | $1.51 | -0.11% |
| Jun 2 | $1.27 | $1.39 | $1.52 | -0.14% |
| Jun 3 | $1.25 | $1.39 | $1.54 | -0.17% |
| Jun 4 | $1.24 | $1.39 | $1.55 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.24 | $1.39 | $1.55 | -0.20% |
| Week 2 | $1.19 | $1.38 | $1.62 | -0.40% |
| Week 3 | $1.14 | $1.38 | $1.67 | -0.59% |
| Week 4 | $1.11 | $1.38 | $1.72 | -0.79% |
| Week 5 | $1.08 | $1.38 | $1.76 | -0.99% |
| Week 6 | $1.05 | $1.37 | $1.79 | -1.18% |
| Week 7 | $1.03 | $1.37 | $1.83 | -1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
ABVC BioPharma, Inc. trades under ABVC and has a current price of $1.39 with a market cap of $36.14M, ranking 4680 by market capitalization. The stock sits in a near-term technical posture described as NEUTRAL, with a 30-day range from $1.06 to $1.82 and a current price near resistance at $1.39 while support sits at $1.02.
The 30-day window shows modest volatility, and the stock carries an implied annualized volatility of 80%.
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 26.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 54.7% above — clearing it would confirm fresh momentum.
Key ABVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.21 | Buy | $1.24 | Buy |
| MA 10 | $1.14 | Buy | $1.18 | Buy |
| MA 20 | $1.10 | Buy | $1.15 | Buy |
| MA 50 | $1.17 | Buy | $1.23 | Buy |
| MA 100 | $1.47 | Sell | $1.47 | Sell |
| MA 200 | $2.12 | Sell | $1.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.59 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 352.59 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 31.13 | Buy |
| Bollinger %B (20,2) | 1.33 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 84.81 | Sell |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 1.29 | Buy |
| ADX (14) | 18.28 | Neutral |
| ATR (14) | 0.04 | Info |
Near term, the technical picture remains NEUTRAL with RSI(14) at 70.0. The stock trades with the 50-day simple moving average at $1.17 and the 200-day simple moving average at $2.12, indicating potential resistance near $1.39 and support near $1.02. The 30-day range spans from $1.06 to $1.82, highlighting limited yet observable movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.909 | $1.39 | $1.98 | 0% | Neutral | |
| $1.05 | $1.39 | $1.98 | 0% | Neutral | |
| $1.08 | $1.50 | $2.25 | +8% | Neutral | |
| $1.03 | $1.48 | $2.30 | +6% | Neutral | |
| $1.07 | $1.59 | $2.56 | +14% | Neutral | |
| $1.31 | $2.01 | $3.34 | +45% | Bullish | |
| $1.43 | $2.26 | $3.84 | +63% | Bullish | |
| $1.48 | $2.39 | $4.17 | +72% | Bullish | |
| $1.35 | $2.24 | $3.99 | +61% | Bullish | |
| $1.27 | $2.18 | $3.94 | +56% | Bullish | |
| $1.69 | $3.26 | $6.41 | +135% | Bullish | |
| $3.21 | $7.13 | $15.71 | +413% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.909 | $1.39 | $1.64 | +0.00% |
| June 2026 | $1.12 | $1.33 | $1.63 | -3.99% |
| July 2026 | $1.13 | $1.35 | $1.69 | +1.50% |
| August 2026 | $1.18 | $1.44 | $1.82 | +6.01% |
| September 2026 | $1.17 | $1.44 | $1.85 | +0.20% |
| October 2026 | $1.14 | $1.41 | $1.83 | -1.86% |
| November 2026 | $1.18 | $1.46 | $1.92 | +3.50% |
| December 2026 | $1.19 | $1.50 | $1.98 | +2.30% |
Click any year to see its month-by-month ABVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABVC could reach as high as $1.98, with a base case around $1.39 and support toward $0.909 — roughly 0% from $1.39. A consolidation phase looks the most probable path here.
Expect ABVC to range from $1.05 to $1.98 through 2027. The $1.39 average target implies a 0% move from current prices. That is 0% versus the projected 2026 average. Price action looks broadly range-bound.
The ABVC price prediction for 2028 points to an average of $1.50 (low $1.08, high $2.25) — a potential gain of +8% on today's $1.39. A consolidation phase looks the most probable path here.
In 2029, ABVC is projected to trade between $1.03 and $2.30, averaging $1.48 — a potential gain of +6% from today's $1.39. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
ABVC BioPharma, Inc.'s 2030 outlook centres on $1.59, within a $1.07 to $2.56 range. That is up +8% on the projected 2029 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, ABVC could reach as high as $3.34, with a base case around $2.01 and support toward $1.31 — roughly +45% from $1.39. Momentum favours further upside here.
Expect ABVC to range from $1.43 to $3.84 through 2032. The $2.26 average target implies a +63% move from current prices. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The ABVC price prediction for 2033 points to an average of $2.39 (low $1.48, high $4.17) — a potential gain of +72% on today's $1.39. Momentum favours further upside here.
In 2034, ABVC is projected to trade between $1.35 and $3.99, averaging $2.24 — a potential gain of +61% from today's $1.39. That is -6% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
ABVC BioPharma, Inc.'s 2035 outlook centres on $2.18, within a $1.27 to $3.94 range. That is -3% versus the projected 2034 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2040, ABVC could reach as high as $6.41, with a base case around $3.26 and support toward $1.69 — roughly +135% from $1.39. Buyers look set to stay in control over this stretch.
Expect ABVC to range from $3.21 to $15.71 through 2050. The $7.13 average target implies a +413% move from current prices. That is up +119% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABVC today (≈ 719.42446 ABVC) could be worth
$5,128.35
+$4,128.35 (+413%) by 2050 · US Dollar
Based on the average projected ABVC price of $7.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABVCwould be worth at today's price.
$1,000 invested in ABVC on May 27, 2025 (≈ 724.637684 ABVC) would be worth
$1,007.25
+$7.25 (+0.7%) today · 1.01× · US Dollar
Based on a ABVC entry price of $1.38 vs. today's $1.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.1 | $1,263.64 | +26.4% |
| 1 month ago | $1.08 | $1,287.04 | +28.7% |
| 3 months ago | $1.29 | $1,077.52 | +7.8% |
| 6 months ago | $2.71 | $512.92 | -48.7% |
| 1 year ago | $1.38 | $1,007.25 | +0.7% |
| All time (5.0y) ago | $53 | $26.23 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABVC forecast.
Our base-case forecast reaches $2.80 around 2040.
Implied market cap at $2.80: $72.8M
Forecasts project a path from neutral to bullish over the coming years. In 2026 the avg is $1.39 with a min of $0.909 and a max of $1.98, ROI 0 and sentiment NEUTRAL. By 2027 the avg remains $1.39 (min $1.05, max $1.98; ROI -0.2, NEUTRAL).
In 2028 the avg rises to $1.50 (min $1.08, max $2.25; ROI 7.7, NEUTRAL), and in 2029 the avg is $1.48 (min $1.03, max $2.30; ROI 6.2, NEUTRAL). The 2030 forecast shows an avg of $1.59 (min $1.07, max $2.56; ROI 14.4, NEUTRAL). Beginning 2031, the outlook turns BULLISH, with 2031 avg $2.01 (min $1.31, max $3.34; ROI 44.8) and continuing through 2035 with avg values of $2.01–$2.39 and ROI 44.8%–72.3%.
By 2040 the avg is $3.26 (min $1.69, max $6.41; ROI 134.7, BULLISH), and by 2050 the avg reaches $7.13 (min $3.21, max $15.71; ROI 412.8, BULLISH). These figures illustrate a long-run upswing with higher potential as years extend, though outcomes remain estimates, not guarantees, and are subject to market and clinical developments.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.59 with a min of $1.07 and a max of $2.56; ROI is 14.4% and sentiment is NEUTRAL.
Near-term sentiment is NEUTRAL, with a long-run bullish trajectory starting in 2031. The 2031–2050 estimates show rising avg prices and substantial ROI, culminating in an average of $7.13 by 2050 and a max of $15.71, but these are estimates and not guarantees.
Yes. The forecast for 2032 lists an avg of $2.26 with a min of $1.43 and a max of $3.84, ROI 62.6, and a BULLISH sentiment, indicating a path above $2 in that period.
$36.14M.
ABVC BioPharma, Inc. Community Discussion
0Share your ABVC BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.